SCHEMBL7222767

SCHEMBL7222767

N#Cc1c[nH]c2ccc(CC(N)=O)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 1/20 0.50
HTR1B P28222 1/20 0.50
SLC6A4 P31645 5/20 0.48
PFKFB2 O60825 1/20 0.48
PFKFB1 P16118 1/20 0.48
PFKFB3 Q16875 1/20 0.48
IMPDH2 P12268 1/20 0.45
IMPDH1 P20839 1/20 0.45
ICMT O60725 5/20 0.45
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
XDH P47989 1/20 0.43
SLC6A2 P23975 2/20 0.42
SLC6A3 Q01959 2/20 0.42
CYP2D6 P10635 1/20 0.42
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5327895 0.78 ALDH1A1 (0.51) SLC6A4KDM4EALDH1A1MEN1MAPT
SCHEMBL7221839 0.78 SLC6A4 (0.51) HTR1DHTR1BSLC6A4PFKFB2PFKFB1
SCHEMBL27664759 0.77 GRIK1 (0.53) SLC6A4PFKFB2PFKFB1PFKFB3IMPDH2
SCHEMBL7222371 0.75 HTR1D (0.51) HTR1DHTR1BICMTKDM4EALDH1A1
SCHEMBL12121424 0.75 SLC6A4 (0.49) HTR1DHTR1BSLC6A4PFKFB2PFKFB1
SCHEMBL12121409 0.75 PFKFB2 (0.47) SLC6A4PFKFB2PFKFB1PFKFB3IMPDH2
SCHEMBL3600581 0.75 PFKFB2 (0.47) SLC6A4PFKFB2PFKFB1PFKFB3IMPDH2
SCHEMBL7221816 0.75 SLC6A4 (0.51) SLC6A4PFKFB2PFKFB1PFKFB3IMPDH2
SCHEMBL10716570 0.74 HTR1A (0.66) HTR1DHTR1BICMTSLC6A2CYP2D6
Methane SCHEMBL10718960 0.73 HTR1A (0.64) HTR1DHTR1BICMTSLC6A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds AVENTIS PHARMACEUTICALS INC. 2003-08-14 US disclosed
US-6541505-B1 Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. AVENTIS PHARMACEUTICALS INC. 2003-04-01 US disclosed
EP-1140901-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2001-10-10 EP disclosed
WO-2000039087-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds SERPINC1, F2, F11 HTR1D 2175/4885HTR1B 1730/4885SLC6A4 4740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.